GENOR-B (06998) has announced that all conditions precedent for the proposed merger have been fulfilled, with the completion taking effect at 9:00 a.m. (Hong Kong Time) on December 30, 2025, which is the effective time of the merger.
The Board is pleased to announce that, following the approval of a special resolution concerning the proposed change of the Company's name at an extraordinary general meeting, the Company's English name has been changed from "Genor Biopharma Holdings Limited" to "Edding Genor Group Holdings Limited."
Concurrently, the Company's dual foreign name in Chinese has been changed from "嘉和生物药业(开曼)控股有限公司" to "亿腾嘉和医药集团有限公司," with both changes effective from 9:00 a.m. (Hong Kong Time) on December 30, 2025, the effective time of the merger.
Pursuant to the merger agreement, following the completion of the merger at 9:00 a.m. (Hong Kong Time) on December 30, 2025, all directors in office immediately prior to the effective time (with the exception of the remaining directors, Mr. Yu Tieming and Mr. Chen Wen) have resigned from their positions.
Effective from the merger's effective time, the Company has appointed Mr. Ni Xin and Ms. Zhai Jing as executive directors; Dr. David Guowei Wang as a non-executive director; and Dr. Xu Qing and Ms. Zheng Jingjing as independent non-executive directors.
Furthermore, Mr. Chen Wen has been re-appointed as an independent non-executive director, with all these directors collectively referred to as the "New Directors."
The remaining director, Mr. Yu Tieming, will continue to serve on the Board as a non-executive director.
Comments